Insulin-Like Growth Factor 1 (IGF-1): Downstream Effects of GH Peptides

# Insulin-Like Growth Factor 1 (IGF-1): Downstream Effects of GH Peptides

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

Insulin-like growth factor 1 (IGF-1) is a 70-amino acid peptide hormone produced primarily by the liver in response to growth hormone (GH) stimulation. It is the primary mediator of GH's anabolic and growth-promoting effects — most of the downstream effects attributed to GH peptides (CJC-1295, Ipamorelin, MK-677) are actually mediated through IGF-1 rather than GH itself.

Understanding IGF-1 biology is essential for interpreting the research on GH secretagogues, as IGF-1 levels are the primary biomarker used to assess GH axis activity in both preclinical and clinical studies.

IGF-1 Synthesis and Regulation

IGF-1 is produced in virtually all tissues, but the liver is the primary source of circulating IGF-1 — accounting for approximately 75% of plasma IGF-1 levels. Hepatic IGF-1 synthesis is stimulated by GH binding to the GH receptor (GHR), a cytokine receptor that activates the JAK2/STAT5 signaling pathway.

STAT5 (Signal Transducer and Activator of Transcription 5) is the primary transcription factor responsible for GH-induced IGF-1 gene expression. When GH binds to GHR, JAK2 kinase phosphorylates STAT5, which dimerizes and translocates to the nucleus to activate IGF-1 gene transcription.

Circulating IGF-1 is bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, which extend its half-life from minutes to hours and regulate its bioavailability. Approximately 75% of circulating IGF-1 exists in a ternary complex with IGFBP-3 and the acid-labile subunit (ALS).

IGF-1 Receptor Signaling

IGF-1 exerts its effects by binding to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase with structural similarity to the insulin receptor. IGF-1R activation triggers two primary downstream signaling pathways:

PI3K/Akt/mTOR pathway: The primary anabolic signaling cascade. IGF-1R phosphorylation recruits IRS-1 (insulin receptor substrate-1), which activates PI3K, generating PIP3. PIP3 recruits and activates Akt (protein kinase B), which phosphorylates multiple substrates: - mTORC1: Activates protein synthesis through S6K1 and 4E-BP1 phosphorylation - FOXO transcription factors: Inhibits atrophy gene expression (MAFbx, MuRF1) - GSK-3β: Promotes glycogen synthesis and inhibits protein degradation

MAPK/ERK pathway: Primarily mediates IGF-1's effects on cell proliferation and differentiation. Activated through Grb2/SOS/Ras signaling downstream of IGF-1R phosphorylation.

IGF-1 and Skeletal Muscle

The most extensively studied effect of IGF-1 is its role in skeletal muscle anabolism. IGF-1 promotes muscle protein synthesis through mTORC1 activation and inhibits muscle protein degradation through FOXO inhibition — a dual mechanism that shifts the net protein balance toward anabolism.

Barton-Davis et al. (1998) demonstrated that local IGF-1 overexpression in aging mouse muscle prevented age-related muscle mass loss and maintained muscle strength. This finding established IGF-1 as a key mediator of muscle aging and provided the rationale for studying GH secretagogues as potential interventions for sarcopenia.

Research on CJC-1295 has consistently demonstrated increases in serum IGF-1 levels following administration, with Teichman et al. (2006) reporting IGF-1 increases of 28-39% above baseline following a single dose in healthy adults.

IGF-1 and Bone

IGF-1 is a major anabolic factor for bone tissue, stimulating osteoblast proliferation and differentiation while inhibiting osteoclast activity. The IGF-1/IGF-1R/PI3K/Akt pathway in osteoblasts promotes bone matrix synthesis and mineralization.

Epidemiological studies have consistently found positive correlations between serum IGF-1 levels and bone mineral density in both men and women. Age-related declines in GH/IGF-1 axis activity are proposed to contribute to the progressive bone loss observed with aging.

IGF-1 and Metabolism

IGF-1 has insulin-like metabolic effects, including stimulation of glucose uptake in muscle and adipose tissue, inhibition of hepatic glucose production, and promotion of lipid oxidation. These effects are mediated through IGF-1R/IRS-1/PI3K/Akt signaling — the same pathway activated by insulin receptor signaling.

The metabolic effects of IGF-1 are relevant to the research on GH secretagogues and metabolic peptides. MK-677, which raises IGF-1 levels through GHS-R1a activation, has been studied for its effects on body composition and insulin sensitivity in aging populations.

IGF-1 and Cancer Risk

A critical consideration in IGF-1 research is the potential relationship between elevated IGF-1 levels and cancer risk. Epidemiological studies have found associations between high-normal IGF-1 levels and increased risk of several cancers, including colorectal, breast, and prostate cancer.

The proposed mechanism involves IGF-1's anti-apoptotic and pro-proliferative effects — properties that are beneficial for normal tissue maintenance but could theoretically promote cancer cell survival and proliferation.

This relationship is an important consideration in the interpretation of GH secretagogue research and underscores the importance of studying these compounds in appropriate research contexts.

References

1. Le Roith, D., et al. (2001). The somatomedin hypothesis: 2001. Endocrine Reviews, 22(1), 53–74.
2. Barton-Davis, E.R., et al. (1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proceedings of the National Academy of Sciences, 95(26), 15603–15607.
3. Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.